Pharmacological effects of ginsenoside Rg1 in neuropsychopharmacology

Panax Ginseng has been used for thousands of years in traditional Chinese medicine(TCM)as a tonic to improver stamina and vitality.Ginsenoside Rg1(Rg1),a saponin extracted from Panax ginseng,is considered one of the most potent pharmacological candidates among TCM.In various diseases related to nervous system,Rg1 has shown excellent pharmacological activities.①Stroke:Rg1 has been well documented to be effective against ischemic/reperfusion(I/R)neuronal injury.A systematic review and meta-analysis revealed a marked efficacy of Rg1 in experi⁃mental acute ischemic stroke,as manifested by its ability to reduce infract volume and improve neurological score.The protective effects of Rg1 were abolished by injecting of AAV-HIF-miR-144-shRNA into the predicted ischemic penumbra.②Depression:In addition,Rg1 showed antidepressive effects in chronic unpredictable mild stress(CUMS)model of depression and in gonadectomized(GDX)model of neuroendocrine disturbance.Rg1 displayed antidepressant activity through the modulation of HPA and HPG axis,markedly alleviated depression-like behavior in rats.Long-term Rg1 treat⁃ment of CUS-exposed rats also significantly prevented the decrease in dye diffusion and improved the ultrastructure of astrocyte gap junctions in the PFC.Rg1 upregulated Cx43 expression in PFC reduced by CUS exposure,indicating beneficial effects on the functional activity of gap junction channels in the brain.③Parkinson disease(PD):Oral treatment with Rg1 significantly attenuated high MPTP-induced mortality,behavior defects,loss of dopamine neurons and abnormal unltrastructure changes in SNpc.It regulated MPTP-induced reactive astrocytes and microglia and decreased the release of cytokines such as TNF-alpha and IL-1βin SNpc.Rg1 also alleviated the unusual MPTP-induced increase in oligomeric,phosphorylated and disease-relatedα-synuclein in SNpc.④Alzheimer disease(AD):Okadaic acid(OKA)intracerebroventricular injection induced memory impairment,including changes in the ability of orientation navigate,spatial probe and relearning memory in behavioral test of Morris water maze(MWM).OKA treated rats showed memory impair⁃ment including increasing of phospho-tau,decreasing of phospho-GSK3βand the formation ofβ-amyloid in special brain regions,which were reversed by Rg1.The possible neuroprotective mechanism might be that Rg1 decreases OKAinduced memory impairment through GSK3β/tau signaling pathway and/or attenuating Aβformation.Meanwhile,Rg1 activated ERK/MAPK pathway by CaMKIIα,and the activation of CREB was not only dependent on ERK induced by Rg1.Additionally,Rg1 inhibited microglial activation by suppressing Iba1 expression.Rg1 inhibited the inflammation mediated by LPS through suppressing NF-κB and MAPK pathway,which provided the explanation for its therapeutic ef⁃fect on neurodegenerative diseases.

29th CINP World Congress of Neuropsychopharmacology

Time:June 22-26,2014Venue:Vancouver Convention Center,Vancouver,Canada Email:cinp@northernnetworking.co.uk Website:www.cinp2014.com The 29th CINP World Congress will be held in June 22-26,2014 in Vancouver,Canada.The main purpose of this CINP World Congress is to provide a truly outstanding scientific and educational program featuring leading figures from around the world who are literally changing the face of neuropsychopharmacology.

29th CINP World Congress of Neuropsychopharmacology

Time:June 22-26,2014Venue:Vancouver Convention Center,Vancouver,Canada Email:cinp@northernnetworking.co.uk Website:www.cinp2014.com The 29th CINP World Congress will be held in June 22-26,2014 in Vancouver,Canada.The main purpose of this CINP World Congress is to provide a truly outstanding scientific and educational program featuring leading figures from around the world who are literally changing the face of neuropsychopharmacology.The Plenary Speakers will include nobel laureates,and other innovators who are transforming our ability to visualize

29th CINP W orld Congress of Neuropsychopharmacology

Time:June 22-26,2014Venue:Vancouver Convention Center,Vancouver,Canada Email:cinp@northernnetworking.co.uk Website:www.cinp2014.com The 29th CINP World Congress will be held in June 22-26,2014 in Vancouver,Canada.The main purpose of this CINP World Congress is to provide a truly outstanding scientific and educational program featuring leading figures from around the

Innovation of Neuropsychopharmacological Experimental Methods to Investigate Attention in Human Participants and Its Validation by Randomized Double Blind Placebo Controlled Clinical Trial

In terms of advancement of life to meet the challenges new method for neuropsychopharmacological research are continually developing to ensure superior safety, accuracy, efficacy, precision etc. In this experiment, we suggested and validated two neuropsychopharmacological testing methods, these are Numeral Finding (NF) and Typo Revealing (TR) tests for the determination of attention in healthy aged human participants. The objective of this experiment was to generate more effective testing methods for the assessment of attention in human. The rationality of the aforementioned methods was checked by a randomized double blind placebo controlled clinical trial for the period of 21 days among healthy aged human participants. The experiment was conducted at Gazipur Sadar, Gazipur-1703, Dhaka, Bangladesh between the period of December 2015 and March 2016. The experiment center was the Department of Pharmacy, Southeast University, Dhaka-1213, Bangladesh. In this experiment, 60 healthy male participants between the age ranges of 40 to 50 years old were selected and randomly divided by simple randomization process into 3 groups with 20 participants in each. Ginkgo biloba standardized extract’s capsule (Giloba? and Kobi?) was used as a standard and as a placebo control psyllium seed husk (i.e., seed of the Plantago ovata) was used after filling in the hard gelatin capsule shell (size 0). Group 1 was treated with Giloba? in which each capsule contained 120 mg Ginkgo biloba standardized extract (GBG) and group 2 was treated with Kobi? in which each capsule contained 60 mg Ginkgo biloba standardized extract (GBK). The treatment procedure for group 3 was psyllium seed husk’s capsule that served as placebo control (PC). Throughout the experiment each capsule was administered 3 times daily. Treatment with Ginkgo biloba standardized extracts for successive days markedly increased the attention of the participants with respect to PC group. In the NF test, administration of GBG and GBK extracts significantly (P P P < 0.01) increased the attention of the participants on 14th and 21st day as compared to that of PC group. For TR test treatment with GBG and GBK extracts markedly (P P P < 0.01) increased the attention of the participants on 14th and 21st day with respect to PC group. The existing experiment proved that NF and TR tests undoubtedly revealed the attention enhancing activity of the Ginkgo biloba standardized extracts in healthy aged human participants. Consequently, the recommended newly emerging methods can be used for the assessment of attention in human and will create a miracle in the domain of neuroscience.

Innovation and Validation of Neuropsychopharmacological Testing Methods for the Assessment of Memory, Attention and Cognition in Human Participants

To meet the challenges of time searching for the new method for neuropsychopharmacology is still an ongoing process. In this experiment, we proposed and validated three neuropsychopharmacological testing methods, which are Matching Capacity (MC), Dissimilarity Identification (DI) and Sense Making (SM) tests for the estimation of memory, attention and cognition respectively in healthy aged human participants. The purpose of this experiment was to generate more effective testing methods for the determination of memory, attention and cognition in human. To endorse proposed methods a randomized double blind placebo controlled clinical trial was conducted among healthy aged human participants between the period of December 2015 and February 2016. The experiment was conducted at Gazipur Sadar, Gazipur-1703, Dhaka, Bangladesh and the experiment center was the Department of Pharmacy, Southeast University, Dhaka-1213, Bangladesh. In this experiment, 60 healthy male participants between the age of 42 to 50 years were selected and divided into 4 groups with 15 participants in each by simple randomization process. Ginkgo biloba standardized extract’s capsule (Giloba?) and Bacopa monnieri standardized extract’s syrup (Monera?) were used as standard. Psyllium seed husk (i.e., seed of the Plantago ovata) was incorporated in the hard gelatin capsule shell (size 0) to prepare capsule and used as a placebo control of the capsule (PCC). Excipients of oral liquid preparation of vitamin were used to prepare syrup and used as a placebo control of the syrup (PCS). The treatment procedure for group 1 was Ginkgo biloba standardized extract’s capsule (120 mg/capsule), 3 times daily for 21 days;group 2 was treated with Bacopa monnieri standardized extract’s syrup (1.21 g/5 ml), 2 teaspoonfuls, 3 times daily for 21 days. Psyllium seed husk’s capsule and excipients of oral liquid vitamin’s syrup were used as placebo control (PC) for group 3 and group 4 and administered in the similar manner of group 1 and group 2, respectively. Administration of Ginkgo biloba (GB) and Bacopa monnieri (BM) standardized extracts for successive days significantly increased the memory, attention and cognition of the participants with respect to PC groups. In the MC test, treatment with GB extract markedly (P < 0.05) increased the memory of the participants on 21st day with respect to PCC group. On the other hand administration of BM extract remarkably (P < 0.01) increased the memory of the participants on 14th day in comparison with PCS group. For DI test, administration of GB extract noticeably (P < 0.01, P < 0.05) increased the attention of the participants on 14th and 21st day as compared to that of PCC group. Conversely BM extract significantly (P < 0.05, P < 0.01) increased the attention of the participants on 7th, 14th and 21st day with regard to PCS group. In the SM test, administration of GB extract noticeably (P < 0.05) increased the cognition of the participants on 7th and 21st day in comparison with PCC group. BM extract administration considerably (P < 0.01) increased cognition of the participants on 14th and 21st day related to the PCS groups. The experiment demonstrates that MC, DI and SM tests clearly exposed the memory, attention and cognition enhancing activity of the GB and BM standardized extracts in healthful aged human participants respectively. Therefore, the proposed method can be used for the fortitude of memory, attention and cognition in human and will generate a landmark in the sphere of neuroscience.

Psychic Neuronal Hypersynchronies: A New Psychiatric Paradigm?

This paper deals with certain psychic automatisms that appear suddenly in the consciousness of the subject in a passive or automatic way and that usually are diagnosed as psychiatric symptoms or manifestations of an epileptic partial seizure. These mental automatisms are described in many writings by mystics, philosophers, literates, composers, and many different great artists and creators from human history, but they did not confer any pathological value on these experiences. The analysis of the epileptogenic activity gives us arguments to propose that these automatic experiences are due to neuronal circuits physiologically adapted to fire in a hypersynchronous way. With these data we enunciate an innovative hypothesis: these psychic experiences are manifestations of an adaptive neuronal network for which we propose the term psychic hypersynchrony. Finally, we discuss the consequences of this hypothesis, especially in the epileptic, psychiatric, and neuropsychopharmacologic fields.